SPYRE THERAPEUTICS, INC. Earnings Per Share (Diluted)
SPYRE THERAPEUTICS, INC. (SYRE) reported Earnings Per Share (Diluted) of -$1.09 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.74.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2024-09-30 was $1.06, a 23.26% increase year-over-year.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2024-06-30 was $0.59, a 98.53% decline year-over-year.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2024-03-31 was $0.72.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was $13.76.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$24.86.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2021 was -$25.02.
- SPYRE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2020 was -$1.52.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.09 10-Q · filed 2026-08-04 | |||||||
| 2026-03-31 | -$0.74 10-Q · filed 2026-05-05 | |||||||
| 2025-09-30 | -$1.24 10-Q · filed 2025-11-04 | |||||||
| 2025-06-30 | -$1.09 10-Q · filed 2025-08-05 | |||||||
| 2024-09-30 | $1.06 10-Q/A · filed 2024-11-18 | -$1.36 10-Q · filed 2024-11-07 | -$2.24 derived: net income ÷ weighted average shares · filed 2025-11-04 | $2.39 10-Q/A · filed 2024-11-18 | -$3.43 10-Q · filed 2024-11-07 | -$5.79 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||
| 2024-06-30 | $0.59 10-Q/A · filed 2024-11-18 | -$0.86 10-Q · filed 2024-08-07 | $1.31 10-Q/A · filed 2024-11-18 | -$2.02 10-Q · filed 2024-08-07 | -$4.49 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$7.31 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||
| 2024-03-31 | $0.72 10-Q/A · filed 2024-11-18 | -$1.20 10-Q · filed 2024-05-09 | -$4.10 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$7.81 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$24.15 derived: net income ÷ weighted average shares · filed 2026-04-10 | |||
| 2023-12-31 | -$4.02 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$10.33 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$40.35 derived: net income ÷ weighted average shares · filed 2026-04-10 | $13.76 10-K/A · filed 2024-11-18 | -$49.12 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $0.86 10-Q/A · filed 2024-11-18 | -$9.34 10-Q · filed 2023-11-09 | -$63.37 derived: net income ÷ weighted average shares · filed 2024-11-18 | $14.65 10-Q/A · filed 2024-11-18 | -$69.57 10-Q · filed 2023-11-09 | -$75.00 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||
| 2023-06-30 | $40.14 10-Q/A · filed 2024-11-18 | -$2.27 10-Q · filed 2023-08-11 | $51.26 10-Q/A · filed 2024-11-18 | -$2.48 10-Q · filed 2023-08-11 | -$66.87 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$71.83 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||
| 2023-03-31 | -$4.89 10-Q · filed 2024-05-09 | -$0.20 10-Q · filed 2023-05-11 | -$9.82 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$14.66 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$3.33 derived: net income ÷ weighted average shares · filed 2026-04-10 | |||
| 2022-12-31 | -$4.93 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$9.77 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$1.98 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$24.86 10-K · filed 2024-02-29 | -$0.99 10-K · filed 2023-03-02 | |||
| 2022-09-30 | -$4.84 10-Q · filed 2023-11-09 | -$0.19 10-Q · filed 2022-11-03 | -$0.94 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$20.17 10-Q · filed 2023-11-09 | -$0.81 10-Q · filed 2022-11-03 | $9.90 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||
| 2022-06-30 | -$0.27 10-Q · filed 2023-08-11 | -$0.63 10-Q · filed 2023-08-11 | $5.26 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$12.74 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||||
| 2022-03-31 | -$0.37 10-Q · filed 2023-05-11 | $0.74 derived: net income ÷ weighted average shares · filed 2026-04-10 | $3.57 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$26.41 derived: net income ÷ weighted average shares · filed 2026-04-10 | ||||
| 2021-12-31 | $0.11 derived: net income ÷ weighted average shares · filed 2026-04-10 | $0.68 derived: net income ÷ weighted average shares · filed 2026-04-10 | $2.59 derived: net income ÷ weighted average shares · filed 2026-04-10 | -$25.02 10-K · filed 2024-02-29 | -$1.00 10-K · filed 2023-03-02 | |||
| 2021-09-30 | -$0.31 10-Q · filed 2022-11-03 | -$0.41 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.69 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | -$0.10 10-Q · filed 2022-08-04 | -$0.38 10-Q · filed 2022-08-04 | ||||||
| 2020-12-31 | -$1.52 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |